MAPT and Alzheimer disease: Next, we compared our results with those from the reference study by Bader et al., which used a similar proteomic pipeline to profile CSF from Aβ+/tau + AD patients across three cohorts (Sweden, Magdeburg/Kiel and Berlin) using a Q Exactive HF-X Orbitrap (17).